Pharming Group reports financial results for the first quarter of 2021

      Financial highlights Operational highlights Post-period operational highlights Chief Executive Officer, Sijmen de Vries, commented: "As previously experienced, the progression of the COVID-19 pandemic has resulted in quarterly fluctuations in revenue. Results in Q1 2021 were negatively affected in the US by a severe COVID-19 surge at the end of 2020 and into 2021. "This caused overstocking of RUCONEST ®  in Q4 2020 and physician office closures...

Netherlands, 13/05/2021 (informazione.news - comunicati stampa - scienza e tecnologia)

 

 

® ®

For the remainder of 2021, the Company expects:

No further specific financial guidance for 2021 is provided.

As previously announced, as of 1 January 2021 , the Company changed its presentation currency from Euro to US Dollar. 

Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

The flagship of our portfolio is our recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that down regulates the complement and contact cascades in order to control inflammation in affected tissues.

Our lead product, RUCONEST®, is the first and only plasma-free rhC1INH protein replacement therapy. It is approved for the treatment of acute hereditary angioedema (HAE) attacks. We are commercializing RUCONEST® in the United States , the European Union and the United Kingdom through our own sales and marketing organization, and the rest of the world through our distribution network.

In addition, we are investigating the clinical efficacy of rhC1INH in the treatment of further indications, including pre-eclampsia, acute kidney injury and severe pneumonia as a result of COVID-19 infections.

We are also studying our oral precision medicine, leniolisib (a phosphoinositide 3-kinase delta, or PI3K delta, inhibitor), for the treatment of activated PI3K delta syndrome, or APDS, in a registration enabling Phase 2/3 study in the United States and Europe .

Furthermore, we are leveraging our transgenic manufacturing technology to develop next-generation protein replacement therapies, most notably for Pompe disease, which is currently in preclinical development.

For further information please visit: www.pharming.com  

Sijmen de Vries, CEO: T: +31 71 524 7400
Susanne Embleton , Investor Relations Manager: T: +31 71 524 7400 E: investor@pharming.com

Victoria Foster Mitchell / Alex Shaw / Amy Byrne
T: +44 203 727 1000

Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

For the period ended 31 March 2021

 

 

 

Appendix: Main Condensed Consolidated Financial Statements reported in Euro's

These statements are not part of the original Interim Financial Statements. The original Interim Financial Statements are reported in US Dollars. In case of differences of interpretation between the Financial Statements in US dollars and the Financial Statements in Euros, the Financial Statements in US Dollars will prevail.

 

 

 

Logo - https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpg